Macular Degeneration

The Burrill Report submits: By Kristi Eaton A new study shows that a cancer drug is no different in effectiveness as a gold standard for macula degeneration. Researchers from Boston University School of Medicine and the VA Boston Healthcare System discovered there was no difference in efficacy between Genentech’s (now Roche’s ( RHHBY.PK )) Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration after six months. Complete Story »

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

Leslie Howard, 76, noticed problems with his right eye in November and was diagnosed with wet age-related macular degeneration (AMD) two months ago. His sight could be saved by a course of treatment involving new drugs which could cost …